ReferenceID 2921
Syringic acid mitigates isoproterenol-induced cardiac hypertrophy and fibrosis by downregulating Ereg
J Cell Mol Med
Gallic acid has been reported to mitigate cardiac hypertrophy, fibrosis and arterial hypertension. The effects of syringic acid, a derivative of gallic acid, on cardiac hypertrophy and fibrosis have not been previously i
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Reference: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final reference record.
- Reference Id
- 2921
- Evidence Id
- 19511
- Core Evidence Id
- 19511
- Source Reference Id
- 5836
- Herb2 Reference Id
- HBREF006633
- Subject Paper Key
- HBIN045292_35719043
- Pubmed Id
- 35719043
- Doi
- 10.1111/jcmm.17449
- Paper Title
- Syringic acid mitigates isoproterenol-induced cardiac hypertrophy and fibrosis by downregulating Ereg
- Paper Abstract
- Gallic acid has been reported to mitigate cardiac hypertrophy, fibrosis and arterial hypertension. The effects of syringic acid, a derivative of gallic acid, on cardiac hypertrophy and fibrosis have not been previously investigated. This study aimed to examine the effects of syringic acid on isoproterenol-treated mice and cells. Syringic acid mitigated the isoproterenol-induced upregulation of heart weight to bodyweight ratio, pathological cardiac remodelling and fibrosis in mice. Picrosirius red staining, quantitative real-time polymerase chain reaction (qRT-PCR) and Western blotting analyses revealed that syringic acid markedly downregulated collagen accumulation and fibrosis-related factors, including Fn1. The results of RNA sequencing analysis of Ereg expression were verified using qRT-PCR. Syringic acid or transfection with si-Ereg mitigated the isoproterenol-induced upregulation of Ereg, Myc and Ngfr. Ereg knockdown mitigated the isoproterenol-induced upregulation of Nppb and Fn1 and enhancement of cell size. Mechanistically, syringic acid alleviated cardiac hypertrophy and fibrosis by downregulating Ereg. These results suggest that syringic acid is a potential therapeutic agent for cardiac hypertrophy and fibrosis.
- Journal
- J Cell Mol Med
- Publish Year
- 2022
- Experiment Subject
- mouse
- Experiment Type
- Animal & Cell Experiment
- Phenotype Related
- Fibrosis; Cardiac Hypertrophy; Arterial Hypertension
- Paper Title Cn
- Paper Title En
- Syringic acid mitigates isoproterenol-induced cardiac hypertrophy and fibrosis by downregulating Ereg
- Bilingual Status
- semi_complete